Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL937953 | 1.00 | HRH4 (0.35) | HRH4GRIN1GRIN2ADRD3PDK1 | |
| SCHEMBL8232360 | 1.00 | HRH4 (0.35) | HRH4GRIN1GRIN2ADRD3PDK1 | |
| SCHEMBL5946959 | 1.00 | HRH4 (0.35) | HRH4GRIN1GRIN2ADRD3PDK1 | |
| SCHEMBL937955 | 1.00 | HRH4 (0.35) | HRH4GRIN1GRIN2ADRD3PDK1 | |
| Bromide SCHEMBL28439253 | 0.98 | HRH4 (0.35) | HRH4GRIN1GRIN2ADRD3PDK1 | |
| Hydrochloric Acid SCHEMBL697063 | 0.98 | HRH4 (0.35) | HRH4GRIN1GRIN2ADRD3PDK1 | |
| Hydrochloric Acid SCHEMBL17314206 | 0.98 | HRH4 (0.35) | HRH4GRIN1GRIN2ADRD3PDK1 | |
| Hydrochloric Acid SCHEMBL17314204 | 0.98 | HRH4 (0.35) | HRH4GRIN1GRIN2ADRD3PDK1 | |
| Hydrochloric Acid SCHEMBL696758 | 0.98 | HRH4 (0.35) | HRH4GRIN1GRIN2ADRD3PDK1 | |
| Hydrochloric Acid SCHEMBL697062 | 0.98 | HRH4 (0.35) | HRH4GRIN1GRIN2ADRD3PDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 206 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025124571-A1 | NMDA RECEPTOR ANTAGONIST AND USE THEREOF | 斯莱普泰(上海)生物医药科技有限公司 | 2025-06-19 | — | — | WO | claimed |
| CN-1099747-A | Benzylhydrazone derivatives, a process for production thereof, and agricultural and horticultural fungicides | NIHON NOHYAKU CO LTD (JP) | 1995-03-08 | — | — | CN | claimed |
| EP-0622355-A2 | Benzylhydrazone derivates, a process for production thereof, and agricultural and horticultural fungicides | NIHON NOHYAKU CO., LTD. (JP) | 1994-11-02 | — | — | EP | claimed |
| CN-1088384-A | Contain the agricultural fungicide and the application thereof of N-(benzyloxy of replacement) imine derivative | NIHON NOHYAKU CO LTD (JP) | 1994-06-29 | — | — | CN | claimed |
| CN-1049654-A | N- (substituted benzyloxy) imine derivatives, process for their preparation, their use and methods of use | NIHON NOHYAKU CO LTD (JP) | 1991-03-06 | — | — | CN | claimed |
| EP-0414153-A1 | N-(substituted benzyloxy)imine derivatives, process for the production thereof, use thereof, and method of use thereof | NIHON NOHYAKU CO., LTD. (JP) | 1991-02-27 | — | — | EP | claimed |
| US-20250223262-A1 | SYNTHESIS OF MORPHINANS WITH REDUCED HERG ACTIVITY AND MOP BINDING | TAROS CHEMICALS GMBH & CO. KG (DE) | 2025-07-10 | — | — | US | disclosed |
| WO-2025124571-A1 | NMDA RECEPTOR ANTAGONIST AND USE THEREOF | 斯莱普泰(上海)生物医药科技有限公司 | 2025-06-19 | — | — | WO | disclosed |
| EP-4499223-A1 | SYNTHESIS OF MORPHINANS WITH REDUCED HERG ACTIVITY AND MOP BINDING | Heinrich-Heine-Universität Düsseldorf (DE) | 2025-02-05 | — | — | EP | disclosed |
| WO-2023187099-A1 | SYNTHESIS OF MORPHINANS WITH REDUCED HERG ACTIVITY AND MOP BINDING | HEINRICH-HEINE-UNIVERSITÄT DÜSSELDORF (DE) | 2023-10-05 | — | — | WO | disclosed |
| US-20230303573-A1 | 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | Grünenthal GmbH (DE) | 2023-09-28 | — | — | US | disclosed |
| EP-3571205-B1 | THIENOPYRIMIDINE DERIVATIVE AND USE THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO LTD (CN) | 2023-08-30 | — | — | EP | disclosed |
| US-20230183184-A1 | 3-(Carboxyethyl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | GRUENENTHAL GMBH (DE) | 2023-06-15 | — | — | US | disclosed |
| US-4587336-A | PARKINSON'S DISEASE | ELI LILLY AND COMPANY (US) | 1986-05-06 | — | — | US | disclosed |
| US-4552956-A | DOPAMINE AGONISTS | ELI LILLY AND COMPANY (US) | 1985-11-12 | — | — | US | disclosed |
| EP-0061900-B1 | MORPHOLINES | JOHN WYETH & BROTHER LIMITED (GB) | 1985-03-20 | — | — | EP | disclosed |
| EP-0061899-B1 | MORPHOLINES | JOHN WYETH & BROTHER LIMITED (GB) | 1985-03-20 | — | — | EP | disclosed |
| US-4409218-A | Analgesic method | JOHN WYETH AND BROTHER LIMITED (GB) | 1983-10-11 | — | — | US | disclosed |
| US-4387097-A | Morpholines | JOHN WYETH AND BROTHER LIMITED (GB) | 1983-06-07 | — | — | US | disclosed |
| EP-0061899-A1 | Morpholines | JOHN WYETH & BROTHER LIMITED (GB) | 1982-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303573-A1 | 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | OPRK1, OPRD1, OPRL1 | HRH4 1326/4885GRIN1 133/4885GRIN2A 22/4885 |
| US-20230183184-A1 | 3-(Carboxyethyl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | OPRK1, OPRD1, PKD2 | HRH4 2163/4885GRIN1 324/4885GRIN2A 80/4885 |
| US-20250223262-A1 | SYNTHESIS OF MORPHINANS WITH REDUCED HERG ACTIVITY AND MOP BINDING | OPRM1, TRPM5, TRPM7 | HRH4 1811/4885GRIN1 434/4885GRIN2A 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.